Sterile Water for Injection Shortage: What Providers and Prescribers Need to Know in 2026

The shortage of Sterile Water for Injection, USP (SWFI) has been an ongoing clinical challenge since 2021 and continues to affect healthcare facilities in 2026. Despite partial recovery following the catastrophic Hurricane Helene-related disruption of Baxter's North Cove, NC manufacturing facility in September 2024, multiple NDC codes remain on allocation or limited availability heading into the second half of 2026. This article provides a clinical overview for prescribers, pharmacists, and infusion providers on managing the ongoing SWFI shortage.

Clinical Overview: What Is Sterile Water for Injection?

Sterile Water for Injection, USP is a sterile, nonpyrogenic, preservative-free preparation of water for injection. It is chemically designated H₂O, with a pH of 5.0–7.0. It is supplied exclusively in single-dose containers and is used only as a pharmaceutical diluent—it must never be administered directly to patients without the addition of a drug or solute. SWFI is NOT isotonic and is labeled with an explicit warning: 'NOT ISOTONIC. HEMOLYTIC.' Intravenous administration of undiluted SWFI can cause red blood cell destruction.

SWFI's primary clinical role is reconstituting lyophilized (freeze-dried) drug products for IV push, IV infusion, intramuscular, or subcutaneous administration. Drugs commonly reconstituted with SWFI include antibiotics (cefazolin, vancomycin, acyclovir), biologics, vaccines, growth hormone, and oncology agents such as alteplase.

Current Shortage Status (2026): What Prescribers Need to Know

The FDA Drug Shortage Database continues to list multiple SWFI NDC codes as of April 2026. The primary manufacturers—Baxter International, Hospira (ICU Medical), Fresenius Kabi/APP, and B. Braun Medical—all show at least some product codes as limited or on allocation. Some codes have estimated recovery dates through September 2026.

The structural cause of the shortage is well-documented: the U.S. IV fluid market is concentrated among four manufacturers, with Baxter alone supplying approximately 60% of the market. This concentration makes the supply chain extremely vulnerable to localized disruptions. The USP's Annual Drug Shortage Reports have repeatedly identified low prices, manufacturing complexity, and geographic concentration as the key drivers of sterile injectable shortages.

Evidence-Based Alternatives to SWFI for Reconstitution

ASHP and peer-reviewed literature support several alternatives when SWFI is unavailable, with the caveat that compatibility must be confirmed for each drug and concentration:

0.9% Sodium Chloride Injection (NS)

NS is the most widely used alternative. Published literature supports NS reconstitution for many antibiotics including acyclovir, cefotaxime, cefazolin (1 g vials at standard concentrations), and others. Key clinical caution: Normal saline reconstitution for IV push administration may produce solutions near saturation for some drugs (e.g., high-concentration cefazolin ≥225 mg/mL) risking crystallization. Do not use prefilled NS flush syringes for reconstitution—these are not designed for this purpose and may contain incompatible concentrations.

Bacteriostatic Water for Injection (BWFI)

BWFI (containing 0.9% benzyl alcohol) is appropriate for many drugs in adult patients. Clinical contraindications: neonates and very small infants (benzyl alcohol toxicity), intrathecal/epidural administration, and medications with preservative-free specifications. Advantage: multi-dose capability with up to 28 days of stability after first use.

Commercially Premixed Formulations

ASHP recommends prioritizing commercially available premixed IV bags and dual-chamber flexible containers to eliminate SWFI reconstitution entirely. Many first-line antibiotics (piperacillin-tazobactam, meropenem, vancomycin) are available as commercially premixed products. Switching order sets to favor premixed formulations is one of the most effective institutional conservation strategies.

Institutional Conservation Strategies

ASHP and NHIA have published formal guidance on SWFI conservation. Key strategies include:

Batching preparation of medications requiring SWFI to minimize vial waste (e.g., bulk-batching alteplase syringes rather than dispensing individual SWFI vials).

Reviewing formulary and order sets to prioritize medications that do not require SWFI reconstitution.

Reserving remaining SWFI exclusively for medications that cannot be safely reconstituted with alternatives.

Identifying medications suitable for oral conversion where clinically appropriate to reduce IV fluid needs.

Using large SWFI bags (1,000 mL or 2,000 mL pharmacy bulk packages) to batch-fill smaller vials or syringes where USP <797> conditions can be maintained.

Patient Communication Guidance

Patients receiving home infusion therapy should be informed proactively about the shortage and any planned substitutions. Key points to communicate:

Any substitution of diluent has been reviewed for compatibility with their specific drug and dose.

They should not attempt to find or substitute alternative waters themselves without guidance.

medfinder (medfinder.com/providers) can help locate pharmacies with current stock if the usual supplier is on allocation.

How medfinder Supports Providers During Shortages

medfinder helps healthcare providers assist their patients in locating hard-to-find medications. By calling pharmacies on behalf of patients, medfinder rapidly identifies which local pharmacies have SWFI in stock—eliminating the burden on clinical staff and ensuring patients don't go without needed medication. Learn more about the provider program at medfinder.com/providers.

For the patient-facing shortage update, see: Sterile Water for Injection Shortage Update: What Patients Need to Know in 2026.